

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 February 2022 (10.02.2022)



(10) International Publication Number
WO 2022/031847 A3

(51) International Patent Classification:
A61K 31/713 (2006.01) *C12N 15/113* (2010.01)

(21) International Application Number:
PCT/US2021/044541

(22) International Filing Date:
04 August 2021 (04.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/061,040 04 August 2020 (04.08.2020) US
63/151,445 19 February 2021 (19.02.2021) US

(71) Applicant: **DICERNA PHARMACEUTICALS INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **BROWN, Bob Dale**; 75 Hayden Avenue, Lex-
ington, Massachusetts 02421 (US). **OSBORN, Maire**; 75
Hayden Avenue, Lexington, Massachusetts 02421 (US).
CHANGELIAN, Armen; 75 Hayden Avenue, Lexington,
Massachusetts 02421 (US). **ZHANG, Chunyang**; 75 Hay-
den Avenue, Lexington, Massachusetts 02421 (US).

(74) Agent: **MANDRAGOURAS, Amy** et al.; 1299 Pennsylva-
nia Ave., NW Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING *PLP1* EXPRESSION




FIG. 1A

(57) Abstract: Oligonucleotides are provided herein that inhibit *PLP1* expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with *PLP1* expression.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

14 April 2022 (14.04.2022)